Search results for: hospital

FDA Approves Combination Therapy for OA Pain, but Not Duobrii Lotion for Plaque Psoriasis

Michele B. Kaufman, PharmD, BCGP | July 9, 2018

The FDA has approved a combination of amlodipine and celecoxib, which may lower serum creatinine, for treating osteoarthritis pain and hypertension…

Anticonvulsants Unhelpful for Low Back Pain

Marilynn Larkin | July 7, 2018

NEW YORK (Reuters Health)—Solid evidence suggests that anticonvulsants provide no benefit for low back or lumbar radicular pain and a high risk of harm, researchers say. “We started the study because these drugs were increasingly being used for low back pain and radiating leg pain, without the support of strong evidence of effectiveness,” principal investigator…

IV Tramadol Promising for Postoperative Pain; FDA Denies IV Meloxicam Approval

Michele B. Kaufman, PharmD, BCGP | July 2, 2018

In its first phase 3 clinical trial, intravenous tramadol has met its primary endpoint for relieving postoperative pain…

FDA Approves Baricitinib for RA Patients

Michele B. Kaufman, PharmD, BCGP | June 25, 2018

The FDA has approved baricitinib in a 2 mg tablet dose to treat patients with moderate to severe active rheumatoid arthritis…

Bringing Policy & Practice Together: A Conversation with GAC Member Ethan Craig, MD, MHS

Carina Stanton | June 21, 2018

In his clinic as a third-year fellow at Johns Hopkins Hospital in Baltimore, Ethan Craig, MD, MHS, says it’s not always easy to hear about patients struggling with step therapy or other barriers to treatment. However, as a member of the ACR’s Government Affairs Committee (GAC), he says his work to understand and improve policy…

ACR’s 2018 Advocates for Arthritis & Advocacy 101 Program

Mary Beth Nierengarten | June 21, 2018

On Sept. 23–25, the ACR will once again hold its annual Advocates for Arthritis fly-in event in Washington, D.C. Held in conjunction with the ACR’s Advocacy 101 course, the fly-in is a great way for members and their patients to learn about issues important to the practice of rheumatology and have the opportunity to actively…

ACR Responds to Drug Pricing Proposals

Mary Beth Nierengarten | June 21, 2018

Responding to the Trump administration’s drug pricing proposals, the ACR released a set of principles it hopes will help guide any drug policy changes.1 The principles underscore what is critically needed for rheumatologists to provide the best and safest care to their patients, many of whom require ongoing treatment for chronic conditions. “The ACR has…

Foundation-Funded Researchers Study Pneumonia Risk, Doc Shortages, Decision Making

From the College | June 21, 2018

In the coming fiscal year (July 1, 2018–June 30, 2019), the Rheumatology Research Foundation has committed to fund more than $9.4 million in rheumatology research and training. Approximately half of the awards will support efforts to recruit and train the next generation of rheumatology professionals. The remaining funds will be awarded to advance research projects…

Food Lover Dr. Joseph Flood Discusses Cooking, Shares Recipe

Carol Patton | June 21, 2018

In addition to the classroom and exam room, the other room Joseph Flood, MD, enjoys spending time in is the kitchen. With a mother who worked as a local tavern cook and a policeman father who enjoyed preparing tasty meals as much as arresting bad guys, Dr. Flood, a rheumatologist at the Columbus Arthritis Center…

Submassive pulmonary embolism. Filling defects seen in the pulmonary artery.

Case Report Illustrates Hypercoagulability in Behçet’s Disease

Aiza Tariq, MD, & Jasim Alidina, MD | June 21, 2018

Behçet’s disease is a chronic, relapsing and remitting vasculitis with multisystem involvement. Commonly referred to as the Silk Road disease due to its prevalence in the Asian and Mediterranean region of the traditional Silk Road, Behçet’s was first described by Hippocrates as a triad of symptoms—genital and oral ulcers with uveitis—and attributed to links with…